For patients living with Type 2 diabetes in the United Kingdom, a more convenient treatment option may be on the horizon after the country’s drug price watchdog recommended Eli Lilly\u2019s once-weekly insulin injectable, Onswik, for coverage on the National Health Service.\u00a0<\/p>\n
The National Institute for Health and Care Excellence (NICE) serves as the U.K.\u2019s drug cost assessor, determining whether a new drug\u2019s price-to-benefit ratio merits coverage via the publicly-funded NHS. The agency’s seal of approval for Onswik means hundreds of thousands of patients with type 2 diabetes could eventually make the switch to a weekly injection and reduce their annual injections by 85%, should Lilly’s long-acting option score approval in the country.\u00a0<\/p>\n
The Onswik option could be particularly valuable to patients who need assistance with their insulin injection because of factors like sight loss, frailty, limited hand movement or difficulty following the necessary steps, according to final draft guidance from NICE issued early Thursday U.K. time.<\/p>\n
Switching to weekly injections also could reduce those patients’ dependence on caregivers and healthcare workers and offer more flexibility in their day-to-day lives, the drug value appraiser added.\u00a0<\/p>\n
A Lilly spokesperson told Fierce that the pharma is now “awaiting a decision from the MHRA on marketing authorization.”\u00a0<\/p>\n
\u201cThis recommendation is\u00a0an important step\u00a0towards giving people with type 2 diabetes greater flexibility in how their condition is managed,\u201d\u00a0 Douglas Twenefour, head of clinical at Diabetes UK, said in a press release.\u00a0Younger patients with type 2 diabetes may also benefit from Onswik if the weekly schedule helps them balance treatment with their working life.\u00a0<\/p>\n
NICE based its recommendation on data from Lilly\u2019s late-stage QWINT-1, QWINT-3, and QWINT-4 clinical trials. The results showed non-inferior A1C reduction with Onswik compared to daily insulin in patients taking insulin for the first time, patients who previously took daily insulin and patients who previously used daily insulin and mealtime insulin. Overall, Onswik controlled blood glucose as well as two commonly used daily insulins, insulin\u00a0degludec\u00a0and\u00a0insulin glargine, and maintained a similar safety profile.\u00a0<\/p>\n
\u201cThis recommendation is the result of\u00a0rigorous, evidence-based decision making, striking a balance between the benefits to patients and the best use of limited NHS funding,\u201d Helen Knight, director of medicines evaluation at NICE, said in a statement.\u00a0<\/p>\n
The endorsement comes at a time when several pharmas, including Lilly<\/a>, have been critical of the agency\u2019s cost-effectiveness evaluations and their influence on the prices paid for new medicines in the U.K.\u00a0<\/p>\n Last year, Merck<\/a> and AstraZeneca<\/a> pressed pause on expansion plans in the U.K., citing an inhospitable environment for drugmakers. And Bristol Myers Squibb threatened to withhold a drug<\/a> from the NHS if the agency wouldn\u2019t match its U.S. price. By the end of 2025, corporations had pulled 2 billion pounds ($2.7 billion) in planned investments in the country.\u00a0<\/p>\n